Interim report Q2, 2023: Strong growth in APAC - Vitrolife AB (publ)
GOTHENBURG, Sweden, July 14, 2023 /PRNewswire/ -- Second quarter
Sales of SEK 905 (829) million, an increase of 9%, or 10% excluding discontinued business. In local currencies the growth was 3% and excluding discontinued business 4%.
Sales, in local currencies and excluding discontinued business, increased by 19% in APAC, and 3% in EMEA, while sales in Americas decreased by 6%.
Sales, in local currencies and excluding discontinued business, increased by 17% in Consumables, Technologies decreased by 7% and Genetic Services decreased by 4%.
Gross margin was 55.8% (56.8), negatively impacted by non-recurring costs of SEK 6 million, giving a run-rate gross margin of 56.5%.
Operating income before depreciation and amortisation (EBITDA) was SEK 293 (273) million. Adjusted for non-recurring costs, EBITDA was SEK 299 million, giving an EBITDA margin of 33.0% (32.9).
Operating cash flow increased to SEK 211 million (180).
Net income was SEK 106 (130) million, including non-recurring costs, resulting in earnings per share of SEK 0.78 (0.96).
First half year
Sales of SEK 1,759 (1,581) million, an increase of 11%, or 13% excluding discontinued business. In local currencies, growth was 5% and excluding discontinued business 6%.
Sales, in local currencies and excluding discontinued business, increased by 21% in APAC, 2% in EMEA and 0% in Americas.
Sales, in local currencies and excluding discontinued business, increased by 14% in Consumables, Technologies growth was 0% and Genetic Services increased by 1%.
Gross margin increased to 56.3% (56.2).
Operating income before depreciation and amortisation (EBITDA) was SEK 554 (501) million. Adjusted for non-recurring costs of SEK 26 million, EBITDA was SEK 580 (501) million, giving an EBITDA margin of 33.0% (31.7).
Operating cash flow increased to SEK 372 million (270).
Net income was SEK 205 (213) million, including non-recurring costs, resulting in earnings per share of SEK 1.52 (1.56).
Gothenburg, July 14, 2023 VITROLIFE AB (publ) Jón Sigurdsson, interim CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 14-07-202308:00 CET.
Hikvision has released its full-year 2023 financial results, reporting a total revenue of RMB 89.34 billion, up 7.42% year-over-year. Net profit attributable to shareholders of the company was RMB 14.11 billion, achieving a year-over-year (YoY)...
Members of the media are invited to join the Honourable Marie-Claude Bibeau, Minister of National Revenue and Member of Parliament for Compton?Stanstead, Lionel Carmant, Minister Responsible for Social Services, and MNA for Taillon, Sherry Romanado,...
Burgundy Diamond Mines (Burgundy or the company) provided its financial and operating results for the first quarter (Q1 2024) ended March 31, 2024 to the Australian Stock Exchange, on April 29, 2024. Burgundy maintained a robust EBITDA of $26...
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective...
The International Horticultural Exhibition 2024 Chengdu kicked off on Friday, attracting hundreds of exhibitors from more than 30 countries.
Ahead of the event, the Chengdu Opening-up and International Cooperation Center organized several seminars...